Online Annex

Table of Contents

[1. Sources and construction of the indicators proposed to measure country responses toward global Covid-19 health equity 1](#_Toc99301426)

[Dimension 1: Financing vaccines, testing and therapeutics 1](#_Toc99301427)

[Dimension 2: Procurement and sharing of vaccine doses 2](#_Toc99301428)

[Dimension 3: Sharing intellectual property and removing export restrictions on medical products 3](#_Toc99301429)

[Indicators considered but not recommended for inclusion 4](#_Toc99301430)

[References 5](#_Toc99301431)

This document provides supplementary material for the Policy Brief, ‘*Monitoring G20 contributions to global Covid-19 health equity: issues and options*’. For each dimension, we outline the sources and construction of each indicator we propose to measure country responses toward global Covid-19 health equity; and discuss other shortlisted indicators that were ultimately not included in the final proposal.

# Sources and construction of the indicators proposed to measure country responses toward global Covid-19 health equity

## Dimension 1: Financing vaccines, testing and therapeutics

Indicator 1.1: ***Contributions to ACT-A 2020–21 and 2021-22 funding rounds as percentage of fair share***

Sources: [Access to COVID-19 tools funding commitment tracker (29 October 2021)](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker); [Access to COVID-19 tools funding commitment tracker](https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker) (2021/22); [ACT 8th Facilitation Council Financing Framework](https://www.google.com/search?q=fair+share+funding+aCT-A+2021-22&oq=fair+share+funding+aCT-A+2021-22&aqs=chrome..69i57.10454j0j7&sourceid=chrome&ie=UTF-8#:~:text=8th%20Facilitation%20Council,act%2Daccelerator%20%E2%80%BA%203_f...) (9 Dec 2021).

Construction: The ACT-A commitment tracker provides data on public pledges as a percentage of each donor’s fair share for 2020/21 and 2011/22 funding rounds (ACT-A 2021a, ACT-A 2021b). This indicator is computed based on pledges made to the 2020/21 round and those made to the 2021/22 round as of 18 March 2022.

Note: The ACT Financial Working Group determines countries’ fair shares: ‘The fair share is determined based on each country’s income level (GDP) and economic openness. It is adjusted to also take into account each country’s GDP per capita, so that countries with the highest levels of income per capita bear a higher contribution. Finally, to collectively reduce the risk of under-contribution by some countries, each country’s fair share is increased by 20%’ (Kanter 2021).

Indicator 1.2: **Share of G20 development assistance in 2020 for the health response to Covid-19 relative to share in G20 GNI**

Sources: Global Burden of Disease 2020 Health Financing Collaborator Network (2021), supplemented by disaggregated country-level data provided by Ian Cogswell (IHME); GNI data is from World Development Indicators

Construction: For each country, we measure the amount of development assistance targeted towards Covid-19 health response as a share of the total G20 contribution, scaled by each country’s Gross National Income (GNI) as a share of total G20 GNI.

## Dimension 2: Procurement and sharing of vaccine doses

Indicator 2.1: ***Total share of the global vaccine supply procured by each G20 country relative to its share in the global population (%)***

Source: [IMF-WHO COVID-19 Vaccine Supply Tracker](https://www.imf.org/en/Topics/imf-and-covid19/IMF-WHO-COVID-19-Vaccine-Tracker)

Construction: We compute the share of the global vaccine supply each G20 procured as of 17 March 2022, relative to its share in the global population. This includes secured doses through supply agreements, domestic production and any donations received – but not optioned doses.

Indicator 2.2: ***Share of surplus vaccines each country has donated to COVAX/AVAT or bilaterally (%)***

Source: [UNICEF Covid Vaccine Market Dashboard](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard) and [IMF-WHO COVID-19 Vaccine Supply Tracker](https://www.imf.org/en/Topics/imf-and-covid19/IMF-WHO-COVID-19-Vaccine-Tracker).

Construction: We compute each country’s surplus secured doses as the number in excess of what would be required to provide two doses to 70% of its population (based on IMF-WHO data from 17 March 2022), then the share of vaccine donations in that total (based on UNICEF data accessed on 20 March 2022).

Indicator 2.3: ***Share of dose donations made through COVAX or AVAT (%)***

Source: [UNICEF Covid Vaccine Market Dashboard](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard)

Construction: We compute the share of doses that have been delivered to COVAX or AVAT as a share of total pledges, as reported as of 20 March 2022. Again, we include as a donation the 580 mn vaccines that the US provided to COVAX through a facilitated cost-sharing arrangement. We do not include commercial supply arrangements with COVAX/AVAT (see section below on ‘Indicators considered by not recommended for inclusion’).

Indicator 2.4: ***Share of vaccine donations that have been delivered (%)***

Source: [UNICEF Covid Vaccine Market Dashboard](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard)

Construction: We compute the share of dose donations delivered to COVAX or to the receiving country as a share of pledges made, according to data accessed on 20 March 2022. We consider the 580 mn vaccines that the US provided to COVAX through a facilitated cost-sharing arrangement as a donation.

## Dimension 3: Sharing intellectual property and removing export restrictions on medical products

Indicator 3.1: ***Whether or not a country supports the TRIPS waiver at the WTO***

Source: MSF (2021) and various media and government sources (available on request)

Construction: The variable has 3 categories, indicating whether it was a co-sponsor of the initial proposal, has subsequently expressed support or is opposed to the waiver.

Indicator 3.2: ***Whether or not a country has endorsed C-TAP***

Source: [World Health Organization](https://www.who.int/initiatives/covid-19-technology-access-pool/endorsements-of-the-solidarity-call-to-action)

Construction: This binary variable indicates whether or not a country has endorsed C-TAP.

NOTE: Indicators 1 and 2 were combined to form a five-point scale depending on country positions on the TRIPs waiver and on C-TAP, as follows:

0 – Do not support TRIPS nor endorse C-TAP

1 – Support C-TAP only (no country falls into this category)

2 – Supports TRIPS but does not endorse C-TAP

3 – Co-sponsor of TRIPS but has not endorsed CTAP, or supports both TRIPS and CTAP

4 – Co-sponsor of TRIPS and supports CTAP

The weight of this scale was then doubled in the final index construction, since it combines two indicators.

Indicator 3.3: ***Number and duration of export restrictions on medical products***

Source: [Global Trade Alert](https://www.globaltradealert.org/reports/54) and computations based on CGD analysis of this data

Construction: Following the methodology used in the CGD Commitment to Development Finance index, as outlined in Robinson et al. (2021), we use Global Trade Alert data on vaccines to construct an indicator that reflects the existence of any export bans, export licensing requirements, export quotas, and export taxes and their duration between the beginning of 2020 and mid 2021. Our focus is on medical products: medical consumables, equipment, medicines or drugs and vaccines.

## Indicators considered but not recommended for inclusion

We identified two additional indicators that are apt measures of the response of key vaccine producers to Covid-19 health equity globally, but because they only pertain to a subset of the G20, we do not propose their inclusion in a composite index covering all G20 countries.

Indicator 1: ***Share of exports supplied to Covax or AVAT (%) [Key vaccine producers]***

Rationale: For exporting countries, we identified the share of exports supplied to Covax or AVAT through commercial agreements, given the importance of these initiatives in distributing vaccines to LICs and MICs.

Source: [WTO-IMF Vaccine Trade Tracker](https://www.wto.org/spanish/tratop_s/covid19_s/vaccine_trade_tracker_s.htm)

Construction: For key exporters, WTO provides data on the volume of exported doses and their composition.[[1]](#footnote-1) We compute the share of exports supplied to Covax or AVAT through supply agreements as a percentage of total exports.

Indicator 2:***Share of exports donated to Covax (%) [Key vaccine producers]***

Rationale: For exporting countries, we are interested in the share of exports that are supplied to Covax or AVAT, given the importance of these initiatives in distributing vaccines to LICs and MICs.

Source: [WTO-IMF Vaccine Trade Tracker](https://www.wto.org/spanish/tratop_s/covid19_s/vaccine_trade_tracker_s.htm)

Construction: For key exporters, WTO provides data on the volume of exported doses and their composition. We compute the share of exports donated to Covax or AVAT as a percentage of total exports.

Limitations for indicators 1 and 2: We cannot discount doses supplied with a short shelf life as this data is not publicly available. Data are available for key producers only and only in summary and cumulated form. We do not have data on any swaps or imports that would allow forming a more complete profile of the vaccine trade.

# References

ACT-Accelerator (2021a) Prioritized Strategy & Budget for 2021, April (<https://www.who.int/publications/m/item/act-a-prioritized-strategy-and-budget-for-2021>)

ACT-Accelerator (2021b), *8th Facilitation Council Financing Framework*, 9 December (<https://www.who.int/docs/default-source/coronaviruse/act-accelerator/3_financing-act-a_8thcouncil_9dec2021.pdf?sfvrsn=a77d4293_1&download=true>)

Cherchye, L., Ooghe, E. and Van Puyenbroeck, T., 2008. Robust human development rankings. The Journal of Economic Inequality, 6(4), pp.287-321.

Global Burden of Disease 2020 Health Financing Collaborator Network (2021) ‘Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050’ *The Lancet* 398: 1317–43.

Kanter, J. (2021), ‘Are Biden’s Global Vaccine Targets Enough – And Will They Mobilize Real Action?’ Global Citizen, September 14 ([Are Biden's Global Vaccine Targets Enough — And Will They Mobilize Real Action? (globalcitizen.org)](https://www.globalcitizen.org/en/content/biden-global-covid-19-vaccine-targets/)).

Médecins san Frontières (2021), ‘Countries obstructing Covid-19 patent waiver must allow negotiations to start’, Webpage, March 9 (<https://www.msf.org/countries-obstructing-covid-19-patent-waiver-must-allow-negotiations>)

McGillivray, M. and White, H., 1993. Measuring development? The UNDP's human development index. *Journal of international development*, *5*(2), pp.183-192.

Robinson, R., Cichocka, B., Ritchie, E. and Mitchell, I. (2021) *The Commitment to Development Index: 2021 Edition, Methodological Overview Paper*, September. Center for Global Development ([cdi-methodology-2021.pdf (cgdev.org)](https://www.cgdev.org/sites/default/files/cdi-methodology-2021.pdf#page=59)).

Silcock, E. and Gulrajani, N., 2020. What is principled aid?. Measuring donor motivations in 2020. Working paper 597. London: (ODI) (<https://cdn.odi.org/media/documents/pai_technical_annex_final.pdf>).

The Global Trade Alert Team (2020), The Covid-19 Pandemic: 21st century approaches to tracking trade policy responses in real-time, Methodological Note, 2 May (<https://www.globaltradealert.org/reports/54>)

1. Excepting Japan, for which only aggregate export figures are provided. We therefore do not include Japan in the set of exporting countries. [↑](#footnote-ref-1)